{"entity":{"id":"nct07570849","kind":"trial","name":"Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma","aka":[],"tldr":"A phase 2 trial of gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, now recruiting.","summary":"Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma is a phase 2 interventional study registered as NCT07570849 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 35 participants, started 2026-03-01 and due to reach its primary completion in 2027-06-01. Interventions recorded: Chidamide, Gemcitabine, cisplatin, immune checkpoint inhibitor. Conditions listed: Intrahepatic Cholangiocarcinoma. Gallbladder cancer is named in the registry entry: \"3. Patients with histologically or pathologically confirmed unresectable or metastatic intrahepatic cholangiocarcinoma (ICC). Patients with extrahepatic cholangiocarcinoma (EHCC) or gallbladder cancer (GBC) are excluded.\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07570849","url":"https://clinicaltrials.gov/study/NCT07570849"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["gemcitabine","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07570849","phase":"2","setting":"Open-label, Phase II Clinical Study of Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma","sponsor":"Shanghai Zhongshan Hospital","participation":[{"nct":"NCT07570849","source":"https://clinicaltrials.gov/study/NCT07570849","fetchedAt":"2026-10-07T16:55:48.977Z","studySha256":"a4feb79258f0143a45b61d33f6bb7c42f4ae819a78542c14a57a706f0b1c309d","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-06","leadSponsor":"Shanghai Zhongshan Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":35,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-03-01","startedType":"actual","enrolled":35,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07570849/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}